Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Agenus Inc (AGEN)

Agenus Inc (AGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 405,073
  • Shares Outstanding, K 137,313
  • Annual Sales, $ 36,780 K
  • Annual Income, $ -159,690 K
  • 60-Month Beta 1.86
  • Price/Sales 10.68
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.43
  • Number of Estimates 3
  • High Estimate -0.36
  • Low Estimate -0.52
  • Prior Year -0.29
  • Growth Rate Est. (year over year) -48.28%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.13 +38.17%
on 08/05/19
2.98 -1.01%
on 08/21/19
+0.49 (+19.92%)
since 07/19/19
3-Month
2.13 +38.17%
on 08/05/19
3.10 -4.84%
on 06/25/19
-0.03 (-1.01%)
since 05/21/19
52-Week
1.54 +91.56%
on 10/30/18
3.88 -23.97%
on 01/18/19
+1.07 (+56.91%)
since 08/21/18

Most Recent Stories

More News
Agenus (AGEN) Q2 Earnings Miss Estimates, Revenues Beat

Agenus (AGEN) reports wider-than-expected loss and beats sales estimates in the second quarter of 2019.

AGEN : 2.95 (+3.15%)
GILD : 64.13 (+1.09%)
ACOR : 3.14 (-2.48%)
GSK : 40.69 (+1.07%)
Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates

Agenus (AGEN) delivered earnings and revenue surprises of -15.15% and 192.92%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

AGEN : 2.95 (+3.15%)
Agenus: 2Q Earnings Snapshot

LEXINGTON, Mass. (AP) _ Agenus Inc. (AGEN) on Thursday reported a loss of $51.9 million in its second quarter.

AGEN : 2.95 (+3.15%)
Agenus Reports Second Quarter 2019 Financial Results and Provides Corporate Update

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1, and cancer vaccines provided corporate updates and reported financial...

AGEN : 2.95 (+3.15%)
Agenus Milestone Triggers $7.5M Payment

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1 and cancer vaccines, announced today that the FDA has accepted the...

AGEN : 2.95 (+3.15%)
Agenus to Report Second Quarter 2019 Financial Results on August 8, 2019 and Host Conference Call and Webcast

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its second quarter 2019 financial results before the market opens...

AGEN : 2.95 (+3.15%)
Agenus Appoints Don Vidic as Vice President and Head of Commercial

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline of novel clinical and preclinical stage checkpoint antibodies, cell therapies and neoantigen vaccines, today announced the appointment...

AGEN : 2.95 (+3.15%)
Agenus (AGEN) Upgraded to Buy: What Does It Mean for the Stock?

Agenus (AGEN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AGEN : 2.95 (+3.15%)
Gilead Inks Deal With Carna Biosciences for Immuno-Oncology

Gilead (GILD) teams up with Carna Biosciences to develop and commercialize small molecule compounds in immuno-oncology.

AGEN : 2.95 (+3.15%)
NVO : 51.82 (+1.05%)
GILD : 64.13 (+1.09%)
GSK : 40.69 (+1.07%)
Why Is Agenus (AGEN) Down 6.3% Since Last Earnings Report?

Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AGEN : 2.95 (+3.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade AGEN with:

Business Summary

Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight diseases. The Company's...

See More

Key Turning Points

2nd Resistance Point 3.06
1st Resistance Point 3.00
Last Price 2.95
1st Support Level 2.87
2nd Support Level 2.79

See More

52-Week High 3.88
Fibonacci 61.8% 2.99
Last Price 2.95
Fibonacci 50% 2.71
Fibonacci 38.2% 2.43
52-Week Low 1.54

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar